Last reviewed · How we verify
Placebo (for Remifentanil)
Placebo produces no pharmacological effect and serves as an inert control in clinical trials to establish the true efficacy of remifentanil through comparison.
Placebo produces no pharmacological effect and serves as an inert control in clinical trials to establish the true efficacy of remifentanil through comparison. Used for Control arm in clinical trials evaluating remifentanil efficacy and safety.
At a glance
| Generic name | Placebo (for Remifentanil) |
|---|---|
| Also known as | Sodium chloride, Normal saline, normal saline |
| Sponsor | University of Nottingham |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Analgesia |
| Phase | FDA-approved |
Mechanism of action
Placebo is a non-active substance used in randomized controlled trials as a comparator arm. In remifentanil studies, placebo allows researchers to distinguish genuine drug effects from natural disease progression, spontaneous improvement, and psychological/expectation-based responses. This enables rigorous assessment of remifentanil's true analgesic and sedative properties.
Approved indications
- Control arm in clinical trials evaluating remifentanil efficacy and safety
Common side effects
Key clinical trials
- Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures (NA)
- Dexmedetomidine and Myocardial Protection (NA)
- Remifentanil for General Anesthesia in the Context of Immaturity (PHASE1, PHASE2)
- Intravenous Administration of Magnesium Sulfate in Laparoscopic Hysterectomy Cases (NA)
- Effect of Liposome Bupivacaine Serratus Plane Block on Postoperative Hyperalgesia and Chronic Post-surgical Pain in Patients Undergoing Radical Mastectomy (PHASE1, PHASE2)
- Intravenous Lidocaine in Carcinologic ENT Surgery: A Trial for Evaluation of Opioid Saving Strategy and Chronic Post-surgical Pain (ELICO) (PHASE3)
- Opioid-Free Anesthesia in Cardiac Surgery (PHASE3)
- Intravenous Administration of Magnesium Sulfate in Hysterectomy Cases (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Remifentanil) CI brief — competitive landscape report
- Placebo (for Remifentanil) updates RSS · CI watch RSS
- University of Nottingham portfolio CI